Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Biogen Receives FDA Approval For Aduhelm

FDA
News

Biogen Receives FDA Approval For Aduhelm

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761178

byBenzinga Newsdesk

February 9, 2023

1 minute read

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761178

Morgan Stanley Downgrades MongoDB to Equal-Weight, Lowers Price Target to $215

By Benzinga Newsdesk

November 21, 7:25 AM

Morgan Stanley analyst Sanjit Singh downgrades MongoDB (NASDAQ:MDB) from Overweight to Equal-Weight and lowers the price target from $368 to $215.

MDB

Movers
News

Digital Turbine Stock Is Tumbling Thursday: What’s Going On?

By Adam Eckert

February 8, 11:16 AM

Digital Turbine Inc (NASDAQ:APPS) shares are trading lower Thursday after the company reported worse-than-expected financial results and issued guidance below analyst estimates.

APPS

Are Alibaba’s Shares a Value Trap? Persistent Low Growth and Merchant Crowding Issues Persist, Analyst Says

By Anusuya Lahiri

June 27, 1:32 PM

Bernstein analyst Robin Zhu downgrades Alibaba Group Holding Ltd (NYSE: BABA) from Outperform to Market Perform, lowering the price

BABA

Benchmark Maintains Buy on Plexus, Raises Price Target to $105

By Benzinga Newsdesk

August 29, 7:34 AM

Benchmark analyst David Williams maintains Plexus (NASDAQ:PLXS) with a Buy and raises the price target from $101 to $105.

PLXS

Biogen Receives FDA Approval For Aduhelm

Related Posts

Morgan Stanley Downgrades MongoDB to Equal-Weight, Lowers Price Target to $215

Digital Turbine Stock Is Tumbling Thursday: What’s Going On?

Are Alibaba’s Shares a Value Trap? Persistent Low Growth and Merchant Crowding Issues Persist, Analyst Says

Benchmark Maintains Buy on Plexus, Raises Price Target to $105